Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences (NASDAQ:ROIV) announced a new $500 million share repurchase program in addition to their previous $1.5 billion program from April 2024. The earlier program, which had $205 million remaining capacity as of March 31, 2025, has now been fully exhausted. The new repurchase program will be funded through available cash and has no expiration date.
The company maintains flexibility in executing the buyback through various methods including open market transactions, tender offers, or private negotiations. Implementation will depend on factors such as share price, market conditions, and alternative investment opportunities. The program can be suspended or discontinued at any time.
Roivant Sciences CFO Richard Pulik reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 20, 2025. The filing details the following key transaction:
- Disposed of 1,503 common shares at a price of $11.45 per share through a "net settlement" transaction (Code F)
- The transaction was related to tax withholding obligations from the vesting and settlement of previously granted RSUs
- Following the transaction, Pulik directly owns 399,056 common shares
The filing was signed by Jo Chen as Attorney-in-Fact for Richard Pulik on June 24, 2025. This routine transaction represents standard tax withholding practices for executive RSU settlements and does not indicate a discretionary sale by the insider.
Roivant Sciences (NASDAQ:ROIV) President & COO Eric Venker reported significant insider transactions on June 20, 2025. The executive exercised 100,000 stock options at $3.85 per share and subsequently sold the same number of shares at an average price of $11.45, realizing a substantial profit. Following these transactions, Venker retains direct ownership of 1,462,223 common shares and 8,238,897 stock options.
The exercised options were part of a grant made in April 2022 with a four-year vesting schedule, including a one-year cliff followed by monthly vesting over three years.
Vivek Ramaswamy, a 10% owner of Roivant Sciences, reported significant insider sales transactions in June 2025. The transactions include:
- June 18, 2025: Sold 565,266 common shares at an average price of $11.45 (range: $11.41-$11.53)
- June 20, 2025: Sold 577,007 common shares at an average price of $11.46 (range: $11.45-$11.54)
Following these transactions, Ramaswamy maintains direct ownership of 37,284,108 common shares and indirect beneficial ownership of 13,357,857 shares through spousal holdings. The total value of shares sold was approximately $13.1 million. These sales represent a notable reduction in his direct holdings but maintain his position as a significant shareholder.
Roivant Sciences Form 144 filing reveals significant insider stock sales by Vivek Ramaswamy, indicating planned disposal of 577,007 shares with an aggregate market value of $6,611,850. The sale is scheduled for June 20, 2025, through Rockefeller Financial LLC on NASDAQ.
Key transaction details:
- Securities originated as Founder Shares acquired on May 7, 2014
- Total outstanding shares: 679,806,070
- Recent trading activity shows substantial sales in past 3 months totaling 2,212,455 shares for approximately $25 million
Previous sales by Ramaswamy in the last 3 months occurred on multiple dates:
- June 18: 565,266 shares ($6.47M)
- June 6: 200,800 shares ($2.25M)
- June 4: 547,430 shares ($6.21M)
- May 7: 625,000 shares ($6.99M)
- May 6: 273,959 shares ($3.14M)
Form 144 Notice of Proposed Sale filed by Eric Venker of Roivant Sciences regarding planned sale of 100,000 common shares through Rockefeller Financial LLC, with an aggregate market value of $1,145,268.08. The shares were acquired through options exercise (grant date 4/20/2022) on 06/20/2025.
Notable recent trading activity by the same insider over the past 3 months:
- June 2-3, 2025: Sold 1 million shares for ~$11.15 million
- May 2025: Disposed of 139,148 shares for ~$1.53 million
- April 2025: Sold 110,945 shares for ~$1.13 million
- March 2025: Divested 760,945 shares for ~$8.31 million
Total shares outstanding: 679,806,070. The proposed sale represents a continuation of significant insider selling activity, with the seller disposing over 2.1 million shares in the past quarter worth approximately $22.12 million.
Vivek Ramaswamy, a key insider at Roivant Sciences, has filed Form 144 indicating a proposed sale of 565,266 common shares with an aggregate market value of $6,472,996.33. The sale is planned to be executed through Rockefeller Financial LLC on the NASDAQ exchange, with an approximate sale date of June 18, 2025.
The shares being sold originated from Founder Shares acquired on May 7, 2014, totaling 58,409,211 shares. The filing reveals significant recent selling activity by Ramaswamy over the past three months:
- June 6, 2025: 200,800 shares for $2,246,311
- June 4, 2025: 547,430 shares for $6,208,008
- May 7, 2025: 625,000 shares for $6,987,388
- May 6, 2025: 273,959 shares for $3,143,287
The company currently has 679,806,070 shares outstanding. This planned sale represents approximately 0.08% of the total outstanding shares.